Skip to main content
ONCIMMUNE HOLDINGS PLC logo

ONCIMMUNE HOLDINGS PLC — Investor Relations & Filings

Ticker · ONC ISIN · GB00BYQ94H38 LEI · 213800HCYIWT6YPI1I02 IL Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2021-06-08 Earnings Release
Country GB United Kingdom
Listing IL ONC

About ONCIMMUNE HOLDINGS PLC

https://www.oncimmune.com/

Oncimmune Holdings PLC is a precision medicine and immunodiagnostics company specializing in the discovery and application of antibody and autoantibody biomarker signatures. The company's core technology is the ImmunoINSIGHTS™ platform, an advanced analytical engine for immune profiling. This platform utilizes a proprietary library of over 9,000 human antigens, bead-based multiplexed immunoassay technology, and machine learning algorithms to generate biological insights from minimal sample volumes. Oncimmune applies its expertise across therapeutic areas including immuno-oncology, autoimmune diseases, and infectious diseases. It provides biomarker discovery services, targeted panels, and advanced bioinformatics to support pharmaceutical and biotechnology partners in developing more effective and targeted treatments and diagnostics.

Recent filings

Filing Released Lang Actions
Full Year Trading Update
Earnings Release Classification · 99% confidence The document is titled "Full Year Trading Update" and provides key financial highlights for the 12 months ended 31 May 2021 (FY21), including revenue figures (£5.6 million) and commentary on future expectations for FY22. It explicitly states: "The Company expects to announce its FY21 results in late September 2021." This indicates the document is a preliminary announcement of financial performance before the full, audited report (like a 10-K or IR) is released. This content aligns perfectly with the definition of an Earnings Release (ER), which provides initial announcements of periodical financial results (key highlights only). The presence of the RNS Number and the LSE footer confirms it is a regulatory announcement, but the content is specifically financial performance summary, making ER the most precise fit over the general RNS fallback. FY 2021
2021-06-08 English
Notice of FY21 Trading Update
Earnings Release Classification · 99% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' and the closing statement referencing RNS as the Primary Information Provider approved by the FCA. The core content is a 'Notice of FY21 Trading Update,' stating that the company *will issue* a trading update on a future date (June 8, 2021). This document itself is not the trading update, the full financial report (10-K or IR), or a transcript. It is an announcement about the publication of future information, including details about analyst and investor presentations related to that future update. This fits the definition of a Report Publication Announcement (RPA) or, given its nature as a general regulatory news item, potentially RNS. Since it specifically announces the publication of a future report/update, RPA is the most precise fit, although RNS is also applicable as the distribution channel. FY 2021
2021-05-28 English
Return of China Rights to EarlyCDT
M&A Activity Classification · 99% confidence The document is identified by the presence of an 'RNS Number' and explicitly states it contains 'inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014'. It announces a specific corporate action: the return of China Rights for the EarlyCDT product portfolio, which is a material event concerning IP and strategic optionality related to accessing US capital markets. This type of announcement, disseminated via the RNS system of the London Stock Exchange, is a general regulatory disclosure that doesn't fit the more specific categories like 10-K (Annual Report), ER (Earnings Release), or CAP (Financing Update), although it touches upon strategic financing options. Since it is a formal, non-standard regulatory announcement distributed through the RNS service, the most appropriate classification is the general regulatory filing category.
2021-05-05 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is a short regulatory announcement dated May 4, 2021, originating from the RNS (Regulatory News Service) of the London Stock Exchange. The content explicitly states it is a disclosure regarding 'Total Voting Rights' pursuant to DTR 5.6, detailing the issued share capital as of April 30, 2021. This type of mandatory disclosure about the total number of shares with voting rights, often triggered by changes like option exercises, fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (like 10-K or IR), a management change (MANG), or a director's dealing (DIRS). Given the explicit mention of 'RNS Number' and the source being RNS, the code RNS is the most appropriate general regulatory filing classification.
2021-05-04 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is a 'TR-1: Standard form for notification of major holdings' issued via RNS (Regulatory News Service) by Oncimmune Holdings PLC. This form is used to report changes in significant share ownership, specifically when a shareholder crosses or reaches a notification threshold. This directly corresponds to the definition of 'Major Shareholding Notification' (MRQ). Although it is distributed via RNS, the core content is a specific regulatory disclosure about share ownership changes, making MRQ the most precise classification over the general RNS fallback.
2021-04-08 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document explicitly starts with 'RNS Number : 7140U' and mentions 'RNS, the news service of the London Stock Exchange' multiple times. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific type of market announcement. Since this is a general regulatory announcement disseminated via the RNS system and does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA), the most appropriate classification is the general regulatory filing category.
2021-04-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.